Perampanel as first add-on choice on the treatment of mesial temporal lobe epilepsy: an observational real-life study
- 9 August 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Neurological Sciences
- Vol. 42 (4), 1389-1394
- https://doi.org/10.1007/s10072-020-04636-7
Abstract
Purpose To evaluate the efficacy of perampanel (PER) in patients with a diagnosis of mesial temporal lobe epilepsy (MTLE) taking PER as first add-on option due to inefficacy of first antiepileptic drug (AED), rather than late add-on choice. Methods Thirty-seven MTLE patients aged ≥ 12 years were recruited consecutively with a minimum duration of follow-up of 1 year and intermediate follow-up of 3 months. Patients were divided into two groups: 20/37 taking PER as first add-on due to inefficacy of first AED (first group) and 17/37 taking PER as late add-on due to inefficacy of ≥ 2 AEDs (second group). Efficacy, retention rate, and safety were evaluated. Results At 3 months, the 70% of the first group had a reduction > 50% of seizure frequency, with six patients becoming also seizure free, while in the second group, only the 23.5% had a reduction > 50% of seizure frequency and none became seizure free (p = 0.005). Six patients of first group were also switched to a monotherapy of PER and five out of six remained seizure free at 12 months. At 1 year of follow-up, efficacy of PER was 70% for the first group, while only of 29.4% for the second group (p = 0.014). Retention rate of the first group at 3 months and 1 year was 85%, while for the second group was, respectively, 82.3% and 64.7%. Conclusion PER was significantly successful and tolerated in MTLE patients when used as first add-on option rather than as late add-on.Keywords
This publication has 19 references indexed in Scilit:
- A retrospective, multicentre study of perampanel given as monotherapy in routine clinical care in people with epilepsySeizure, 2018
- AMPA receptors and perampanel behind selected epilepsies: current evidence and future perspectivesExpert Opinion on Pharmacotherapy, 2017
- Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: The FYDATA studyEpilepsy Research, 2016
- 3‐T magnetic resonance imaging simultaneous automated multimodal approach improves detection of ambiguous visual hippocampal sclerosisEuropean Journal of Neurology, 2015
- Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonistActa Neurologica Scandinavica, 2013
- Adjunctive perampanel for refractory partial-onset seizuresNeurology, 2012
- Perampanel: A novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsyEpilepsia, 2011
- Age at onset predicts good seizure outcome in sporadic non-lesional and mesial temporal sclerosis based temporal lobe epilepsyJournal of Neurology, Neurosurgery & Psychiatry, 2010
- Enhanced Relative Expression of Glutamate Receptor 1 Flip AMPA Receptor Subunits in Hippocampal Astrocytes of Epilepsy Patients with Ammon's Horn SclerosisJournal of Neuroscience, 2004
- Quantitative Autoradiographic Analysis of lonotropic Glutamate Receptor Subtypes in Human Temporal Lobe Epilepsy: Up‐regulation in Reorganized Epileptogenic HippocampusEuropean Journal of Neuroscience, 1997